Equipalazone 1 g Oral Powder - Apple Flavoured
Free flowing white/cream powder for oral administration, containing 1 g micro-encapsulated Phenylbutazone per sachet.
Preservative: Sodium Paracombin 0.15 % w/w
Uses
Equipalazone 1 g Oral Powder is indicated in the treatment of musculoskeletal disorders in horses and ponies where the anti-inflammatory and analgesic properties of Phenylbutazone can offer relief, for example, in lameness associated with osteoarthritic conditions, acute and chronic laminitis, bursitis and carpitis, and in the reduction of post-surgical soft tissue reaction.
Dosage and administration
Dependent on individual response, but as a guide:
Horses: 450 kg (1000 lb) bodyweight:
Two sachets to be administered twice on day one (equivalent to 8.8 mg/kg/day) followed by one sachet twice daily for four days (4.4 mg/kg/day), then one sachet daily or on alternate days sufficient to keep the horse comfortable (2.2 mg/kg/day).
Ponies: 225 kg (500 lb) bodyweight:
One sachet (4.4 mg/kg/day) on alternate days.
Adjust dose according to bodyweight.
Discontinue treatment if no response is evident after four to five days treatment.
For ease of administration, Equipalazone 1 g Oral Powder may be mixed with a small quantity of bran or oats.
Contra-indications, warnings, etc
Treated horses may never be slaughtered for human consumption.
The therapeutic index of Phenylbutazone is low.
Do not exceed the stated dose or the duration of treatment.
Use is contraindicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects.
Use in any animal less than six weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal as there is a risk of increased renal failure.
Concurrent administration of potentially nephrotoxic drugs should be avoided.
It is preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered.
Use during pregnancy should be avoided whenever possible, particularly during the first trimester.
Response to long-term therapy should be monitored ar regular intervals by a veterinary practitioner.
Operator warnings: The product should be handled with care at all times to reduce the risk of accidental ingestion, skin contact or dust inhalation. If accidental skin or eye contact occurs, the site should be washed immediately with water. If the product is ingested, seek medical advice immediately and show the product packaging.
Advice to doctors: gastric lavage (emesis in children) should be performed urgently. Charcoal haemoperfusion has also been shown to be beneficial. Treatment should then be administered symptomatically.
General precautions: For animal treatment only.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections appropriate concurrent antimicrobial therapy should be instigated.
Withdrawal period: Do not use in animals intended for human consumption.
Pharmaceutical precautions
Do not store above 25°C. Store in a dry place. Keep out of the reach and sight of children.
Disposal: Dispose of any unused product and empty containers in accordance with guidance from your national waste regulation authority.
Legal category
POM-V (previously POM)
Packaging Quantities
Boxes of 32 and 100 sachets.
Further information
The clinical effect of Phenylbutazone can be evident for at least three days following cessation of administration. This should be borne in mind when examining horses for soundness.
Some authorities (including the Jockey Club) regard Phenylbutazone as a "prohibited substance" under the rules of competition. Therefore, use of this product in a competition horse should be in accordance with the recommendations/advice of the relevant competition authorities.
To be supplied only on veterinary prescription.
Veterinary medicinal product authorised for use in UK and Ireland.
Equipalazone 1 g Oral Powder - Apple Flavoured
Free flowing white/cream powder for oral administration, containing 1 g micro-encapsulated Phenylbutazone per sachet.
Preservative: Sodium Paracombin 0.15 % w/w
Uses
Equipalazone 1 g Oral Powder is indicated in the treatment of musculoskeletal disorders in horses and ponies where the anti-inflammatory and analgesic properties of Phenylbutazone can offer relief, for example, in lameness associated with osteoarthritic conditions, acute and chronic laminitis, bursitis and carpitis, and in the reduction of post-surgical soft tissue reaction.
Dosage and administration
Dependent on individual response, but as a guide:
Horses: 450 kg (1000 lb) bodyweight:
Two sachets to be administered twice on day one (equivalent to 8.8 mg/kg/day) followed by one sachet twice daily for four days (4.4 mg/kg/day), then one sachet daily or on alternate days sufficient to keep the horse comfortable (2.2 mg/kg/day).
Ponies: 225 kg (500 lb) bodyweight:
One sachet (4.4 mg/kg/day) on alternate days.
Adjust dose according to bodyweight.
Discontinue treatment if no response is evident after four to five days treatment.
For ease of administration, Equipalazone 1 g Oral Powder may be mixed with a small quantity of bran or oats.
Contra-indications, warnings, etc
Treated horses may never be slaughtered for human consumption.
The therapeutic index of Phenylbutazone is low.
Do not exceed the stated dose or the duration of treatment.
Use is contraindicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects.
Use in any animal less than six weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal as there is a risk of increased renal failure.
Concurrent administration of potentially nephrotoxic drugs should be avoided.
It is preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered.
Use during pregnancy should be avoided whenever possible, particularly during the first trimester.
Response to long-term therapy should be monitored ar regular intervals by a veterinary practitioner.
Operator warnings: The product should be handled with care at all times to reduce the risk of accidental ingestion, skin contact or dust inhalation. If accidental skin or eye contact occurs, the site should be washed immediately with water. If the product is ingested, seek medical advice immediately and show the product packaging.
Advice to doctors: gastric lavage (emesis in children) should be performed urgently. Charcoal haemoperfusion has also been shown to be beneficial. Treatment should then be administered symptomatically.
General precautions: For animal treatment only.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections appropriate concurrent antimicrobial therapy should be instigated.
Withdrawal period: Do not use in animals intended for human consumption.
Pharmaceutical precautions
Do not store above 25°C. Store in a dry place. Keep out of the reach and sight of children.
Disposal: Dispose of any unused product and empty containers in accordance with guidance from your national waste regulation authority.
Legal category
POM-V (previously POM)
Packaging Quantities
Boxes of 32 and 100 sachets.
Further information
The clinical effect of Phenylbutazone can be evident for at least three days following cessation of administration. This should be borne in mind when examining horses for soundness.
Some authorities (including the Jockey Club) regard Phenylbutazone as a "prohibited substance" under the rules of competition. Therefore, use of this product in a competition horse should be in accordance with the recommendations/advice of the relevant competition authorities.
To be supplied only on veterinary prescription.
Veterinary medicinal product authorised for use in UK and Ireland.
Shipping charges mainland GB zone1
| Value | Weight | Delivery Charge |
| Over £49.00 | Any Weight | FREE |
| Under £49.00 | No weight limit | £4.50 |
| Under £49.00 | Under 250 grams | £3.49 |
Most orders are despatched the same day and standard delivery is 3 to 5 working days from despatch. FAST Expedited options are available at extra cost - these usually arrive in 24-48hrs from dispatch but delays are possible during busy periods.
Postcodes outside of Zone 1 (including some areas within mainland UK) may incur extra carriage charges due to surcharges imposed by the couriers. These will be calculated on the website at the checkout.
NB: Orders placed with faster delivery must be placed before 13:00 to ensure same day dispatch (excluding weekends and bank holidays). Please also check on the product page that the items ordered show 'In Stock' otherwise your order will be delayed until the stock becomes available, which in most cases will only be 24hrs.
Estimated "Usually shipped in" information is shown against most products
Overseas orders
We no longer send goods outside of the UK.
Prescription Items
Prescription items will be sent on receipt of a legally valid signed and dated prescription.
Pick up
We offer a pickup service for orders placed over the phone.
Please ring us on 01833 641112 for more information.
Refrigerated Items
- Refrigerated lines Packaging Cost: Despatched with Woolcool Refrigerated Packaging for £7.50.
- Receipt Required: Someone must be available to receive the delivery. Woolcool packaging is designed for temperature-controlled goods, so parcels cannot be left unattended.
- Immediate Refrigeration: Upon receipt, refrigerate the contents immediately to ensure your food or medicine remains at the correct temperature.
- Failed Delivery Attempts: We are not responsible for the cost of replacements if a delivery attempt fails due to the absence of someone to receive it.
We want you to be completely satisfied with any purchase. If not any item* can be returned to us within 14 days of receipt for exchange or refund Please give us a ring for a returns number on 01833 641112 or alternatively email sales@hyperdrug.co.uk to obtain a returns number.
*Due to legal requirements medicines may not be returned except to correct an error in despatch or in response to an "official recall". If an item is believed to be faulty it should be returned for inspection and it may be necessary to forward it to the manufacturers for testing before replacements or refunds can be authorised. This does not infringe legal rights. Please contact our customer services for a "Returns Number" which must appear on the outside of the package or it will not be accepted. We advise customers to use an insured method of shipping and to retain proof of despatch. We may refuse returns on products specially obtained or manufactured to order. Items must be returned unsoiled and unused and sent adequately packed and carriage paid.
